Multiple Basal Cell Carcinomas Mimicking Segmental Neurofibromatosis: A Clinical Conundrum
Main Article Content
Keywords
basal cell carcinoma, segmental basal cell carcinoma, vismodegib, neurofibroma, case report
Abstract
Basal cell carcinomas (BCC) are the most common type of skin cancer, typically presented as pearly pink papules on areas of the body with chronic ultraviolet (UV) exposure. Sporadic segmental BCC has been rarely reported in the literature and can often be mistaken for other skin conditions, such as segmental neurofibromatosis or inherited segmental basal cell nevus syndrome. A comprehensive clinical history, a detailed physical examination with dermoscopy, and maintaining a high index of suspicion for biopsy allowed us to achieve an accurate diagnosis. Initiating targeted therapy with Vismodegib resulted in rapid clinic improvement and a significant enhancement in the patient’s quality of life.
References
2. Friedman JM. Neurofibromatosis 1. 1998 Oct 2 [Updated 2022 Apr 21]. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1109/
3. Gabhane SK, Kotwal MN, Bobhate SK. Segmental neurofibromatosis: a report of 3 cases. Indian J Dermatol. 2010;55(1):105-108. doi:10.4103/0019-5154.60366
4. Terada T. Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases. Med Oncol. 2013;30(1):444. doi:10.1007/s12032-012-0444-0
5. Paulson KG, Iyer JG, Nghiem P. Asymmetric lateral distribution of melanoma and Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2011;65(1):35-39. doi:10.1016/j.jaad.2010.05.026
6. Khamaysi Z, Bochner R, Indelman M, et al. Segmental basal cell naevus syndrome caused by an activating mutation in smoothened. Br J Dermatol. 2016;175(1):178-181. doi:10.1111/bjd.14425
7. Bree AF, Shah MR; BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS).Am J Med Genet A2011;155A:2091–7.
8. Baczynski A, Cahn B, Worley B, Haber R, Alam M. Oral smoothened inhibitors for Gorlin syndrome: A clinical review. J Am Acad Dermatol. 2024;91(4):706-711. doi:10.1016/j.jaad.2024.06.047
9. Trinh P, Li S, Sarin KY. Neurofibromatosis Type 1 and Risk of Skin Cancer. JAMA Dermatol. 2022;158(10):1214–1216. doi:10.1001/jamadermatol.2022.3083
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.